Thromboembolic events (TEEs) are a rare, but serious adverse event for patients receiving immunoglobulin therapy. Patient and product-specific risk factors can increase the risk for these adverse ...

When you hear the term "immunoglobulin," you might have the intuition that because it is a drug that administers antibodies, ...

A case report in BMC Pediatrics documents severe delayed-onset chlorothiazide-induced immune thrombocytopenia in a former ...

After years of specialists, inconclusive tests and more questions than answers, Hilary Eaton turned to ChatGPT to help make sense of her daughter Olivia’s complex symptoms ...

Good morning, and welcome to the Kyverna Therapeutics Conference Call. [Operator Instructions] Please note, this call is being recorded. I would now like to introduce Jessica Serra, Head of Investor ...

Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line ...

Five-year overall survival rate was reported at 69.2%, indicating strong long-term efficacy of CARVYKTI in treating ...

As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an ...

A coating of a petroleum-based polymer called polyethylene glycol (PEG) is used to protect many nanomedicines from the attention of the immune system and give them time to work. Studies show, however, ...

Martin T, Usmani S, Berdeja JG, et al. Ciltacabtagene autoleucel in patients with heavily pretreated relapsed/refractory multiple myeloma: 5-year follow-up from CARTITUDE-1. Blood. 2024;144 (suppl ...

Adding intravenous immunoglobulin (IVIG) to high-dose prednisone was associated with greater symptom improvement than prednisone alone in adults with newly diagnosed idiopathic inflammatory myopathies ...